🇺🇸 FDA
Patent

US 7220853

Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1

granted A61KA61K38/00A61K48/00

Quick answer

US patent 7220853 (Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1) held by The Board of Regents of the University of Texas System expires Mon May 17 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue May 22 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 17 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K38/00, A61K48/00, A61P, A61P35/00